Idiopathic Pulmonary Fibrosis (IPF) Clinical Trial
Official title:
Idiopathic Pulmonary Fibrosis, a Disease Initiated by Mucociliary Dysfunction
This study seeks to screen first degree family members of people with Idiopathic Pulmonary Fibrosis (IPF) for the earliest signs of lung fibrosis.
The purpose of this study is to explore genetic factors associated with the development of pulmonary fibrosis. The investigators aim is to identify and explore genetic loci that affect development of pulmonary fibrosis and also explore related environmental exposures. Idiopathic pulmonary fibrosis (IPF) is one of the interstitial lung diseases under the broader umbrella of idiopathic interstitial pneumonias (IIP). The investigators hypothesize that inherited genetic factors are associated with pulmonary fibrosis. To investigate the genetics of pulmonary fibrosis, the investigators plan to enroll individuals with pulmonary fibrosis and their family members. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04497831 -
Morphine for Dyspnea in Pulmonary Fibrosis
|
Phase 3 | |
| Recruiting |
NCT05119972 -
Tolerability, Pharmacokinetics and Efficacy of ZSP1603 in Patients With Idiopathic Pulmonary Fibrosis （IPF）
|
Phase 1/Phase 2 | |
| Completed |
NCT01718990 -
Biomarker Discovery for Novel Drug Development in Idiopathic Pulmonary Fibrosis
|
||
| Completed |
NCT00162760 -
Treatment of Idiopathic Pulmonary Fibrosis With Thalidomide
|
Phase 2 | |
| Terminated |
NCT04589260 -
TD-1058 First-In-Human Study in Healthy Subjects and Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Completed |
NCT04069143 -
A Study to Evaluate the Safety, Tolerability, Kinetics and Repeatability of 18F-BMS-986327
|
Phase 1 | |
| Completed |
NCT03050255 -
Short-term Effects of Supplemental Oxygen in Patients With IPF
|
N/A | |
| Terminated |
NCT02013700 -
Allogeneic Human Cells (hMSC)in Patients With Idiopathic Pulmonary Fibrosis Via Intravenous Delivery (AETHER)
|
Phase 1 | |
| Active, not recruiting |
NCT04598919 -
Saracatinib in the Treatment of Idiopathic Pulmonary Fibrosis
|
Phase 1/Phase 2 | |
| Completed |
NCT03981094 -
A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy Participants
|
Phase 1 | |
| Completed |
NCT02758808 -
Pulmonary Fibrosis Foundation Patient Registry
|
||
| Not yet recruiting |
NCT05387785 -
Study to Assess the Safety and Tolerability of ANG-3070 in Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 1 | |
| Active, not recruiting |
NCT05938920 -
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT02538536 -
A Phase 2 Study to Evaluate the Safety and Tolerability of PBI-4050 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT01371305 -
STX-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Withdrawn |
NCT03720483 -
Inhaled NAC in Treatment of IPF
|
Phase 1/Phase 2 | |
| Recruiting |
NCT05975983 -
Study Evaluating INS018_055 Administered Orally to Subjects With Idiopathic Pulmonary Fibrosis
|
Phase 2 | |
| Completed |
NCT03650075 -
To Determine Safety and Tolerability of MG-S-2525 and to Evaluate Its PK Profile in Healthy Volunteers
|
Phase 1 | |
| Completed |
NCT03832946 -
A Study to Test the Efficacy and Safety of Inhaled GB0139 in Subjects With Idiopathic Pulmonary Fibrosis (IPF)
|
Phase 2 | |
| Completed |
NCT02874989 -
Targeting Pro-Inflammatory Cells in Idiopathic Pulmonary Fibrosis: a Human Trial
|
Phase 1 |